The Blood-Saving Effect of Vasopressinergic V1 Receptor Agonists in Urologic Oncology

Onkourologiya - Russian Federation
doi 10.17650/1726-9776-2017-13-3-119-123
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Publishing House ABV Press

Related search

History of Urologic Oncology in Turkey: Bladder Cancers

Üroonkoloji Bülteni
2015English

Guest Editorial: Robotic Techniques in Urologic Oncology

World Journal of Urology
Urology
2013English

Evaluation and Management of the Geriatric Urologic Oncology Patient

Current Geriatrics Reports
GerontologyGeriatrics
2014English

876 the Impact of Resident Involvement in Minimally Invasive Urologic Oncology Procedures

European Urology, Supplements
Urology
2014English

A Clinician's Guide to Statistical Methods in Urologic Oncology

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2008English

Beyond Classic Risk Adjustment: Socioeconomic Status and Hospital Performance in Urologic Oncology Surgery

Cancer
Cancer ResearchOncology
2018English

Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?

Open Journal of Endocrine and Metabolic Diseases
2016English

The Cardiovascular Effects of GLP-1 Receptor Agonists

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2010English

Thrombopoietin Receptor Agonists for the Treatment of Inherited Thrombocytopenia

Haematologica
Hematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy